A Phase 2 interventional study of GSK1278863 and rhEPO in Anaemia, sponsored by GlaxoSmithKline. Completed at 62 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-11-14.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 15th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 2, and was the 4th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 17th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 2, and was the 9th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68 hemodialysis-dependent subjects with anemia associated with chronic kidney disease. The study consists of a screening phase of 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study eligibility is 9.5-12.0 g/dL and the subjects must have received the same rhEPO product with total weekly doses that varied by no more than 50% during the 4 weeks prior to the Screening visit (Week -1. This study aims to estimate the relationship between dose of GSK1278863 and Hgb response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease after switching from a stable maintenance dose of recombinant human erythropoetin (rhEPO).
This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68 hemodialysis-dependent subjects with anemia associated with chronic kidney disease. The study consists of a screening phase of 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study eligibility is 9.5-12.0 g/dL and the subjects must have received the same rhEPO product with total weekly doses that varied by no more than 50% during the 4 weeks prior to the Screening visit (Week -1. Eligible subjects, stratified by their prior rhEPO dose will be randomized in equal proportions to receive double-blind GSK1278863 0.5 mg, 2 mg or 5 mg QD (after discontinuing their rhEPO), or to continue to receive their existing type and dose of rhEPO (epoetins or their biosimilars, or darbepoetin). Study treatment will be stopped if Hgb values fall outside of the protocol pre-specified ranges. Subject completion is defined as completion of all study phases including the follow-up phase.
This study aims to estimate the relationship between dose of GSK1278863 and Hgb response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease after switching from a stable maintenance dose of recombinant human erythropoetin (rhEPO). In addition, the study will characterize the effect of GSK1278863 on various pharmacokinetic (PK)/pharmacodynamic (PD) markers, and will investigate the safety and tolerability of GSK1278863.
An early interim analysis of the Hgb data is planned after approximately 20 subjects from cohort 1 have completed 3 weeks of treatment. Depending upon the interim findings, a second cohort of subjects may be added to investigate an additional GSK1278863 dose arm. Recruitment to the first cohort will continue during the interim analysis.
A second interim analysis is planned after approximately 48 subjects from cohort 1 have completed 4 weeks treatment. The purpose of this interim is three-fold, to investigate if a second cohort of subjects may be added, to facilitate early development of dose-response and PK/PD statistical models, and to generate interim results to facilitate design and dosing decisions for the next trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hypertension: Poorly controlled hypertension, whether due to inadequate treatment, or lack of treatment, is defined as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily
Drug: GSK1278863
once daily
Drug: GSK1278863
once daily
Drug: GSK1278863
as required
Drug: rhEPO
tablet
injection
Modeled Hemoglobin (Hgb) Change From Baseline (Pre-dose on Day 1) at 4 Weeks of Treatment
Modeled Hgb change from Baseline over 4 weeks of treatment. Change from Baseline is the actual value of Hgb at Week 4 minus the Baseline value. For modeled change at Week 4 participants required a Baseline and two or more non missing post-baseline values. Baseline is the average of Week -2, -1 and Day 1 values. The model included fixed effects for Baseline Hgb, treatment, and treatment by day interaction. Covariate analysis for modeled Hgb change was performed. Random effects were fitted in the intercept and the slope over time.
Time frame: Baseline (pre-dose on Day 1) and up to week 4
Hgb Variability Over 4 Weeks
Within participant standard deviation for Hgb acts as a measure of Hgb variability. Hgb of participants was recorded over 4 weeks.
Time frame: Up to 4 weeks
Evaluation of Change From Baseline in Hepcidin Over Period
Evaluation of change from baseline for hepcidin was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the last pre-dose value. Adjusted mean change from Baseline is presented as Least square (LS) mean.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of Change From Baseline (Pre-dose on Day 1) in High Sensitivity C-Reactive Protein (hsCRP) Over 4 Weeks
Evaluation of change from Baseline for hsCRP was analyzed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the last pre-dose value. Peak change from Baseline also was calculated; however adjusted mean change from Baseline has been presented here as LS means.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Change From Baseline for Erythropoeitin (EPO) Over Period
Evaluation of change from Baseline (pre-dose on Day 1) for EPO was analyzed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the pre-dose Day 1 value. Adjusted means are presented as LS means.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of Change From Baseline (Pre-dose on Day 1) for Peak Vascular Endothelial Growth Factor (VEGF) Over 4 Weeks
Evaluation of change from Baseline for peak VEGF was analyzed up to 4 weeks. Baseline assessment was performed pre-dose on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Absolute mean change and peak change from Baseline in peak VGEF were also calculated; however, only model adjusted peak change in peak VGEF from Baseline has been presented as LS means.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of Change From Baseline (Pre-dose on Day 1) for Hematocrit Over 4 Weeks
Evaluation of change from Baseline for hematocrit over 4 weeks was performed. Change from Baseline is the value at indicated time point minus the Baseline value.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Residual Standard Deviation in Hgb (From the Linear Regression)
Residual standard deviation was derived by linear regression. Hgb of participants was recorded over 4 weeks
Time frame: Up to 4 weeks
Number of Days Spent Within Hgb Range ( ±0.5 g/dL and ±1 g/dL ) From Baseline Hgb
Time spent with Hgb within range (where range was defined as +-0.5 g/dL and +-1 g/dL from baseline Hgb ) was analyzed. Baseline value of Hgb was recorded pre-dose on Day 1.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Evaluation of Change From Baseline (Pre-dose on Day 1) in Ferritin Over 4 Weeks
Change from Baseline (pre-dose on Day 1) in ferritin over 4 weeks was analyzed. Change from Baseline is the value at indicated time point minus the Baseline value. Model adjusted mean has been presented as LS mean.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Evaluation of Change From Baseline (Pre-dose on Day 1) for Transferrin Over 4 Weeks
Evaluation of change from Baseline for ferritin was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Model adjusted mean has been presented as LS mean.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Change From Baseline (Pre-dose on Day 1) for Transferrin Saturation Over 4 Weeks
Transferrin saturation is a medical laboratory test and is the ratio of serum iron and total iron-binding capacity, multiplied by 100 and expressed as a ratio. Evaluation of change from baseline for transferrin saturation was performed up to 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline value was recorded pre-dose on Day 1. Model adjusted mean values are presented as LS mean values.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Change From Baseline (Pre-dose on Day 1) for Total Iron Over 4 Weeks
Evaluation of change from Baseline for total iron was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was recorded pre-dose on Day 1. Adjusted mean was presented as LS mean.
Time frame: Baseline (pre-dose on Day 1) and at Week 4
Change From Baseline (Pre-dose on Day 1) in Total Iron Binding Capacity Over 4 Weeks
Evaluation of change from Baseline in total iron binding capacity was performed over 4 weeks. Baseline was recorded pre-dose on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Adjusted means are presented as LS means.
Time frame: Baseline (pre-dose on Day 1) and Week 4
Change From Baseline (Pre-dose on Day 1) for Red Blood Cells (RBCs) Over 4 Weeks
Change from Baseline in RBCs was a pharmacodynamic (PD) biomarker. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was recorded pre-dose on Day 1. Change from Baseline (pre-dose on Day 1) in RBCs was calculated over 4 weeks.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Change From Baseline (Pre-dose on Day 1) for Reticulocytes Over 4 Weeks
Evaluation of change from Baseline for reticulocytes was a PD parameter. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline value was recorded pre-dose on Day 1.
Time frame: Baseline (pre-dose on Day 1) and up to 4 weeks
Number of Participants Reaching Hgb Stopping Criteria
Participants were analyzed whether they had any increase or decrease from the Baseline Hgb. Hgb increase based stopping criteria included analysis of Increase or decrease of more than or equal to (\>=) 2 g/dL from the Baseline (pre-dose on Day 1) was recorded and also the participants with hemoglobin \>=13 g/dL were recorded.
Time frame: Up to 4 weeks
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. An SAE is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above. Only on-treatment data has been presented.
Time frame: Up to 4 weeks
Number of Participants Discontinuing the Study Treatment Due to AEs
Discontinuation of the study drug could be due to safety-related reasons AE. The AEs responsible included anemia, gastrointestinal hemorrhage, and nausea.
Time frame: Up to 4 weeks
Mean Plasma Concentration of GSK1278863 and GSK1278863 Metabolites Over 4 Weeks
Each of the plasma concentration-time plot contained one plot on the untransformed scale (i.e. a linear plot) and one plot on the log transformed scale (i.e. log-linear plot). Plasma concentrations were analyzed for the study drug (GSK1278863), and its metabolites namely GSK2391220 (M2), GSK2531403 (M3), GSK2487818A (M4), GSK2506102A (M5), GSK2531398 (M6), and GSK2531401A (M13). Pharmacokinetic analysis was done on Weeks (W) 2 and 4 at a fixed timely interval of 5 hours (h) on W2 and every hour on W4. Only the data for last visit for W2 and last visit of W4 has been presented.
Time frame: Up to 4 weeks
Number of Participants With Abnormal Hematology and Clinical Chemistry Parameters of Potential Clinical Concern (PCI)
Participants were analyzed up to 6 weeks for hematological and clinical chemistry parameters of PCI whether they had any higher or lower values than the reference range post screening. Normal alkaline phosphatase (ALP) was 0-46 U/L, aspartate amino transferase (AST) 0-42 U/L, ALP 20-125 U/L, total bilirubin 0-1.3 mg/dL, troponin 0-0.1ng/mL, Hgb 12 - 16 g/dL, platelets 140-450 G/L, creatine phosphokinase 29-168 U/L, creatinine 0.57 - 1.25 mg/dL, Potassium 3.6-5.0 mmol/L, hematocrit 38-45%; however, no participants with abnormal hematology and clinical chemistry parameters were recorded.
Time frame: Up to 6 weeks (including follow-up)
Number of Participants With Abnormal Vital Signs of PCI
Vital signs include systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Three measurements of SBP, DBP and HR were recorded from the participant in a supine position for at least 5 minutes (allowing enough time between measurement to completely deflate and loosen the inflatable cuff). Data has been presented for vital signs with values high and low from the reference range.
Time frame: Up to 6 weeks
Number of Participants With Electrocardiogram (ECG) Findings Over Period
Participants were analyzed for any abnormality in ECG and was categorized as abnormal clinically significant and abnormal and clinically insignificant. The parameters that were analyzed for ECG were atrial fibrillation, Atrial premature complex, Bigeminy, First degree AV block (PR interval \> 200 msec), Incomplete right bundle branch block, Junctional rhythm, Junctional tachycardia (heart rate \>100 beats/min), Left anterior hemi block (synonymous to left anterior fascicular block), Left atrial abnormality, Left axis deviation (QRS axis more negative than -30 degrees), Left bundle branch block, Left ventricular hypertrophy, Myocardial infarction, anterior, Myocardial infarction, inferior, Non-specific ST-T changes, Normal sinus rhythm, Poor R wave progression, Right atrial abnormality, Right QRS axis deviation, bundle block, ventricular hypertrophy, ST depression or abnormality, AV block, arrhythmia, short PR interval, bradycardia, tachycardia, and T-wave abnormality.
Time frame: Up to 6 weeks
This study was conducted in hemodialysis-dependent (HDD) participants from 06 June 2012 till 17 June 2013 across 48 centers in the United States (US), Canada, and European Union. A total of 68 participants were planned to be enrolled.
| Milestone | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Started | 21 | 21 | 21 | 20 |
| Completed | 17 | 17 | 17 | 19 |
| Not completed | 4 | 4 | 4 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 2 | 1 |
| Withdrew: Met hemoglobin stopping criteria | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
Modeled Hgb change from Baseline over 4 weeks of treatment. Change from Baseline is the actual value of Hgb at Week 4 minus the Baseline value. For modeled change at Week 4 participants required a Baseline and two or more non missing post-baseline values. Baseline is the average of Week -2, -1 and Day 1 values. The model included fixed effects for Baseline Hgb, treatment, and treatment by day interaction. Covariate analysis for modeled Hgb change was performed. Random effects were fitted in the intercept and the slope over time.
| Grams per deciliter (g/dL) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Modeled Hemoglobin (Hgb) Change From Baseline (Pre-dose on Day 1) at 4 Weeks of Treatment | -1.130 ± 0.6830 | -1.070 ± 0.7703 | 0.212 ± 0.7521 | -0.273 ± 0.6335 |
Within participant standard deviation for Hgb acts as a measure of Hgb variability. Hgb of participants was recorded over 4 weeks.
| g/dL | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Hgb Variability Over 4 Weeks | 0.53 ± 0.271 | 0.55 ± 0.325 | 0.40 ± 0.364 | 0.35 ± 0.193 |
Evaluation of change from baseline for hepcidin was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the last pre-dose value. Adjusted mean change from Baseline is presented as Least square (LS) mean.
| Micrograms per liter (mcg/L) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Evaluation of Change From Baseline in Hepcidin Over Period | 204.88 ± 60.741 | 150.29 ± 62.619 | 16.42 ± 62.815 | -45.47 ± 61.939 |
Evaluation of change from Baseline for hsCRP was analyzed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the last pre-dose value. Peak change from Baseline also was calculated; however adjusted mean change from Baseline has been presented here as LS means.
| Milligrams per liter (mg/L) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Evaluation of Change From Baseline (Pre-dose on Day 1) in High Sensitivity C-Reactive Protein (hsCRP) Over 4 Weeks | -0.40 ± 1.784 | -4.76 ± 1.834 | -1.48 ± 1.886 | -2.92 ± 1.784 |
Evaluation of change from Baseline (pre-dose on Day 1) for EPO was analyzed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was the pre-dose Day 1 value. Adjusted means are presented as LS means.
| Units per liter (U/L) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Change From Baseline for Erythropoeitin (EPO) Over Period | 4.368 ± 73.3485 | 3.263 ± 73.5023 | 181.948 ± 77.7763 | 393.159 ± 71.4855 |
Evaluation of change from Baseline for peak VEGF was analyzed up to 4 weeks. Baseline assessment was performed pre-dose on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Absolute mean change and peak change from Baseline in peak VGEF were also calculated; however, only model adjusted peak change in peak VGEF from Baseline has been presented as LS means.
| Nanograms per liter (ng/L) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Evaluation of Change From Baseline (Pre-dose on Day 1) for Peak Vascular Endothelial Growth Factor (VEGF) Over 4 Weeks | 23.21 ± 12.110 | 21.52 ± 12.291 | 53.85 ± 12.645 | 20.59 ± 12.874 |
Evaluation of change from Baseline for hematocrit over 4 weeks was performed. Change from Baseline is the value at indicated time point minus the Baseline value.
| Percentage | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Week 1 | -0.59 ± 1.609 | -0.16 ± 1.823 | -0.75 ± 1.735 | 0.20 ± 1.738 |
| Week 2 | -1.33 ± 2.122 | -1.56 ± 2.296 | -0.75 ± 1.960 | 2.02 ± 8.248 |
| Week 3 | -2.32 ± 2.634 | -2.22 ± 2.712 | -0.65 ± 2.277 | 0.24 ± 2.507 |
| Week 4 | -3.22 ± 2.731 | -2.63 ± 3.006 | -0.33 ± 2.044 | -0.22 ± 2.874 |
Residual standard deviation was derived by linear regression. Hgb of participants was recorded over 4 weeks
| g/L | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Residual Standard Deviation in Hgb (From the Linear Regression) | 0.24 ± 0.108 | 0.26 ± 0.115 | 0.26 ± 0.309 | 0.20 ± 0.112 |
Time spent with Hgb within range (where range was defined as +-0.5 g/dL and +-1 g/dL from baseline Hgb ) was analyzed. Baseline value of Hgb was recorded pre-dose on Day 1.
| Days | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Within +/- 0.5 g/dL | 12.82 (6.98 to 21.85) | 14.34 (4.86 to 25.76) | 24.41 (8.94 to 28.00) | 21.15 (10.50 to 28.00) |
| Within +/- 1 g/dL | 27.71 (19.25 to 28.00) | 20.79 (12.76 to 28.00) | 28.00 (24.77 to 28.00) | 28.00 (23.33 to 28.00) |
Change from Baseline (pre-dose on Day 1) in ferritin over 4 weeks was analyzed. Change from Baseline is the value at indicated time point minus the Baseline value. Model adjusted mean has been presented as LS mean.
| Micrograms per liter | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Evaluation of Change From Baseline (Pre-dose on Day 1) in Ferritin Over 4 Weeks | 76.7 ± 36.31 | -1.6 ± 37.41 | -76.7 ± 38.48 | -38.0 ± 37.27 |
Evaluation of change from Baseline for ferritin was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Model adjusted mean has been presented as LS mean.
| Grams per liter | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Evaluation of Change From Baseline (Pre-dose on Day 1) for Transferrin Over 4 Weeks | 0.105 ± 0.0699 | 0.155 ± 0.0719 | 0.221 ± 0.0737 | 0.059 ± 0.0703 |
Transferrin saturation is a medical laboratory test and is the ratio of serum iron and total iron-binding capacity, multiplied by 100 and expressed as a ratio. Evaluation of change from baseline for transferrin saturation was performed up to 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline value was recorded pre-dose on Day 1. Model adjusted mean values are presented as LS mean values.
| Ratio | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Change From Baseline (Pre-dose on Day 1) for Transferrin Saturation Over 4 Weeks | 6.4 ± 3.33 | 11.7 ± 3.34 | 1.3 ± 3.42 | -0.1 ± 3.24 |
Evaluation of change from Baseline for total iron was performed over 4 weeks. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was recorded pre-dose on Day 1. Adjusted mean was presented as LS mean.
| Micromoles per Liter | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Change From Baseline (Pre-dose on Day 1) for Total Iron Over 4 Weeks | 4.3 ± 1.44 | 6.2 ± 1.47 | 2.5 ± 1.51 | 0.3 ± 1.43 |
Evaluation of change from Baseline in total iron binding capacity was performed over 4 weeks. Baseline was recorded pre-dose on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Adjusted means are presented as LS means.
| Micromoles per Liter | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Change From Baseline (Pre-dose on Day 1) in Total Iron Binding Capacity Over 4 Weeks | 3.2 ± 1.05 | 3.7 ± 1.06 | 5.2 ± 1.08 | 1.3 ± 1.03 |
Change from Baseline in RBCs was a pharmacodynamic (PD) biomarker. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline was recorded pre-dose on Day 1. Change from Baseline (pre-dose on Day 1) in RBCs was calculated over 4 weeks.
| 10^12 cells per Liter (Giga cells per L) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Week 1 | -0.04 ± 0.157 | -0.03 ± 0.189 | -0.06 ± 0.184 | 0.02 ± 0.177 |
| Week 2 | -0.13 ± 0.191 | -0.14 ± 0.243 | -0.05 ± 0.210 | 0.18 ± 0.771 |
| Week 3 | -0.22 ± 0.248 | -0.19 ± 0.305 | -0.05 ± 0.229 | 0.01 ± 0.256 |
| Week 4 | -0.29 ± 0.259 | -0.25 ± 0.337 | -0.03 ± 0.198 | -0.03 ± 0.262 |
Evaluation of change from Baseline for reticulocytes was a PD parameter. Change from Baseline is the value at indicated time point minus the Baseline value. Baseline value was recorded pre-dose on Day 1.
| Percentage change | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Week 1 | -0.42 ± 0.966 | -0.56 ± 0.751 | 0.03 ± 0.681 | -0.08 ± 0.837 |
| Week 2 | -0.45 ± 1.072 | -0.49 ± 0.613 | -0.08 ± 0.656 | -0.14 ± 0.737 |
| Week 3 | -0.34 ± 1.114 | -0.27 ± 0.757 | -0.06 ± 0.634 | -0.35 ± 0.782 |
| Week 4 | -0.36 ± 1.030 | -0.26 ± 0.533 | -0.03 ± 0.703 | -0.29 ± 0.686 |
Participants were analyzed whether they had any increase or decrease from the Baseline Hgb. Hgb increase based stopping criteria included analysis of Increase or decrease of more than or equal to (\>=) 2 g/dL from the Baseline (pre-dose on Day 1) was recorded and also the participants with hemoglobin \>=13 g/dL were recorded.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Post Baseline Hgb <8.0 | 1 | 1 | 0 | 0 |
| >=2g/dL Hgb increase post Baseline | 0 | 1 | 1 | 0 |
| Post Baseline Hgb >=13.0 | 0 | 0 | 1 | 0 |
An AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. An SAE is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above. Only on-treatment data has been presented.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Any AE | 9 | 7 | 1 | 6 |
| Any SAE | 0 | 2 | 0 | 2 |
Discontinuation of the study drug could be due to safety-related reasons AE. The AEs responsible included anemia, gastrointestinal hemorrhage, and nausea.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Number of Participants Discontinuing the Study Treatment Due to AEs | 1 | 2 | 0 | 0 |
Each of the plasma concentration-time plot contained one plot on the untransformed scale (i.e. a linear plot) and one plot on the log transformed scale (i.e. log-linear plot). Plasma concentrations were analyzed for the study drug (GSK1278863), and its metabolites namely GSK2391220 (M2), GSK2531403 (M3), GSK2487818A (M4), GSK2506102A (M5), GSK2531398 (M6), and GSK2531401A (M13). Pharmacokinetic analysis was done on Weeks (W) 2 and 4 at a fixed timely interval of 5 hours (h) on W2 and every hour on W4. Only the data for last visit for W2 and last visit of W4 has been presented.
| Nanograms per milliliter (ng/mL) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 |
|---|---|---|---|
| GSK1278863, Week 2, 7-11h | 0.2292 ± 0.40031 | 3.3148 ± 5.89540 | 5.6170 ± 15.91725 |
| GSK1278863, Week 4, 3h | 3.3113 ± 3.14336 | 17.9009 ± 12.89917 | 34.7253 ± 38.79049 |
| M2, Week 2, 7-11h | 0.4582 ± 0.28340 | 1.5468 ± 1.11679 | 4.3165 ± 3.03668 |
| M2, Week 4, 3h | 0.6780 ± 0.42493 | 2.0382 ± 1.98534 | 7.4288 ± 3.64287 |
| M3, Week 2, 7-11h | 0.6386 ± 0.35940 | 2.1188 ± 1.60771 | 5.6935 ± 3.24262 |
| M3, Week 4, 3h | 0.7921 ± 0.42785 | 2.2857 ± 2.03968 | 8.4582 ± 3.55548 |
| M4, Week 2, 7-11h | 0.2156 ± 0.19430 | 0.8121 ± 0.69622 | 2.3216 ± 2.75137 |
| M4, Week 4, 3h | 0.6016 ± 0.45551 | 1.8355 ± 1.89643 | 6.1856 ± 3.24320 |
| M5, Week 2, 7-11h | 0.1546 ± 0.11679 | 0.5511 ± 0.41077 | 1.4581 ± 0.71612 |
| M5, Week 4, 3h | 0.1995 ± 0.22453 | 0.7132 ± 1.08288 | 1.9972 ± 0.71061 |
| M6, Week 2, 7-11h | 0.1776 ± 0.12140 | 0.6956 ± 0.47561 | 1.8957 ± 1.47442 |
| M6, Week 4, 3h | 0.3235 ± 0.27845 | 1.0626 ± 1.35895 | 3.4569 ± 1.56093 |
| M13, Week 2, 7-11h | 0.4875 ± 0.38599 | 1.4014 ± 1.19096 | 3.9647 ± 1.86947 |
| M13, Week 4, 3h | 0.4651 ± 0.35442 | 1.3623 ± 1.40324 | 5.3494 ± 2.60236 |
Participants were analyzed up to 6 weeks for hematological and clinical chemistry parameters of PCI whether they had any higher or lower values than the reference range post screening. Normal alkaline phosphatase (ALP) was 0-46 U/L, aspartate amino transferase (AST) 0-42 U/L, ALP 20-125 U/L, total bilirubin 0-1.3 mg/dL, troponin 0-0.1ng/mL, Hgb 12 - 16 g/dL, platelets 140-450 G/L, creatine phosphokinase 29-168 U/L, creatinine 0.57 - 1.25 mg/dL, Potassium 3.6-5.0 mmol/L, hematocrit 38-45%; however, no participants with abnormal hematology and clinical chemistry parameters were recorded.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Number of Participants With Abnormal Hematology and Clinical Chemistry Parameters of Potential Clinical Concern (PCI) | 0 | 0 | 0 | 0 |
Vital signs include systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Three measurements of SBP, DBP and HR were recorded from the participant in a supine position for at least 5 minutes (allowing enough time between measurement to completely deflate and loosen the inflatable cuff). Data has been presented for vital signs with values high and low from the reference range.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| DBP, low | 1 | 2 | 2 | 3 |
| DBP, high | 2 | 2 | 0 | 2 |
| SBP, low | 0 | 1 | 0 | 1 |
| SBP, high | 10 | 9 | 6 | 10 |
| HR, low | 0 | 0 | 0 | 0 |
| HR, high | 0 | 0 | 3 | 2 |
Participants were analyzed for any abnormality in ECG and was categorized as abnormal clinically significant and abnormal and clinically insignificant. The parameters that were analyzed for ECG were atrial fibrillation, Atrial premature complex, Bigeminy, First degree AV block (PR interval \> 200 msec), Incomplete right bundle branch block, Junctional rhythm, Junctional tachycardia (heart rate \>100 beats/min), Left anterior hemi block (synonymous to left anterior fascicular block), Left atrial abnormality, Left axis deviation (QRS axis more negative than -30 degrees), Left bundle branch block, Left ventricular hypertrophy, Myocardial infarction, anterior, Myocardial infarction, inferior, Non-specific ST-T changes, Normal sinus rhythm, Poor R wave progression, Right atrial abnormality, Right QRS axis deviation, bundle block, ventricular hypertrophy, ST depression or abnormality, AV block, arrhythmia, short PR interval, bradycardia, tachycardia, and T-wave abnormality.
| Participants | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| Abnormal, clinically significant | 10 | 12 | 8 | 12 |
| Abnormal, not clinically significant | 5 | 6 | 9 | 6 |
Collected over Up to 4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5 mg GSK1278863 | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| 2 mg GSK1278863 | 0/21 (0%) | 2/21 (9.5%) | 1/21 (4.8%) |
| 5 mg GSK1278863 | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| rhEPO | 0/20 (0%) | 2/20 (10%) | 0/20 (0%) |
| Event | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| HyperkalemiaMetabolism and nutrition disorders | 0/21 | 0/21 | 0/20 | 1/20 |
| Pulmonary edemaRespiratory, thoracic and mediastinal disorders | 0/21 | 0/21 | 0/20 | 1/20 |
| ConstipationGastrointestinal disorders | 0/21 | 1/21 | 0/20 | 0/20 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 0/21 | 1/21 | 0/20 | 0/20 |
| Event | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO |
|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 3/21 | 1/21 | 0/20 | 0/20 |
The intent to treat (ITT) population included all randomized participants who received at least one dose of the study drug, had a baseline and at least one corresponding on treatment laboratory assessment.
| Age, Continuous(Years) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO | Total |
|---|---|---|---|---|---|
| Mean | 56.4 ± 16.80 | 54.7 ± 18.78 | 55.9 ± 18.37 | 64.2 ± 12.77 | 57.8 ± 16.92 |
| Sex: Female, Male(Participants) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO | Total |
|---|---|---|---|---|---|
| Female | 3 | 7 | 8 | 4 | 22 |
| Male | 18 | 13 | 11 | 16 | 58 |
| Race (NIH/OMB)(Participants) | 0.5 mg GSK1278863 | 2 mg GSK1278863 | 5 mg GSK1278863 | rhEPO | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 3 | 2 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 4 | 4 | 18 |
| White | 14 | 14 | 12 | 14 | 54 |
| More than one race | 0 | 0 | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from May 2012 to primary completion in May 2013, 12 months.
Results were first posted in Sep 2017, 4 years 3 months after primary completion. A results delay was requested in Apr 2015.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 12 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863